RocheSwiss pharma giant Roche announced that its investigational BTK inhibitor fenebrutinib sharply reduced multiple sclerosis relapses in Phase III studies. However, death imbalances cloud the picture.
Tag Archive for: relapsing multiple sclerosis
Roche’s bruton’s tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.